Bifogade filer
PDF
Kurs
+16,42%
Likviditet
2,71 MSEK
Kalender
| Tid* | ||
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-11-08 | - | Extra Bolagsstämma 2021 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-22 | - | X-dag ordinarie utdelning FOLLI 0.00 SEK |
| 2021-06-21 | - | Årsstämma |
| 2021-05-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-05 | - | X-dag ordinarie utdelning FOLLI 0.00 SEK |
| 2020-06-04 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Kvartalsrapport 2019-Q3 |
| 2019-09-24 | - | Extra Bolagsstämma 2019 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-07 | - | X-dag ordinarie utdelning FOLLI 0.00 SEK |
| 2019-06-05 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-13 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-04 | - | Extra Bolagsstämma 2018 |
| 2018-05-31 | - | X-dag ordinarie utdelning FOLLI 0.00 SEK |
| 2018-05-30 | - | Årsstämma |
| 2018-05-24 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-24 | - | Kvartalsrapport 2017-Q3 |
| 2017-09-27 | - | Extra Bolagsstämma 2017 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-27 | - | X-dag ordinarie utdelning FOLLI 0.00 SEK |
| 2017-04-26 | - | Årsstämma |
| 2017-02-24 | - | Bokslutskommuniké 2016 |
| 2016-11-25 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-26 | - | Kvartalsrapport 2016-Q2 |
| 2016-06-14 | - | X-dag ordinarie utdelning FOLLI 0.00 SEK |
| 2016-06-13 | - | Årsstämma |
| 2016-05-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-01 | - | Extra Bolagsstämma 2016 |
| 2016-02-24 | - | Bokslutskommuniké 2015 |
| 2015-11-30 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-21 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-22 | - | Kvartalsrapport 2015-Q1 |
| 2015-04-29 | - | Årsstämma |
| 2015-02-26 | - | X-dag ordinarie utdelning FOLLI 0.00 SEK |
| 2015-02-25 | - | Bokslutskommuniké 2014 |
| 2014-11-27 | - | Kvartalsrapport 2014-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Follicum AB today announces that Jonas Edelswärd has been appointed as new CFO. He succeeds Fredrik Werner, who has decided to leave his position after 2 years in the company. Jonas Edelswärd will take up his position on 10 May.
Jonas Edelswärd, with a MSc in Economics has more than 20 years of experience from various positions in high-tech startups. He has also worked with more mature companies when he acted as CEO of the investment company AB Axel Granlund in Malmö. Jonas Edelswärd is chairman of the board of Zaplox AB, board member of Galenica AB, Pragati AB and Humanus Utbildning Syd AB and deputy board member of Galerie Leger AB. During the period July 2018 to June 2019, he was a board member of Follicum.
"I am pleased to welcome Jonas Edelswärd as the new CFO. He knows Follicum well following his time on the Company's Board of Directors and has extensive experience in supporting innovative companies in their development. I would also like to take this opportunity to thank Fredrik Werner for his significant efforts and wish him all the best in the future", says Kim Arvid Nielsen, CEO of Follicum.
For further information, please contact:
Kim Arvid Nielsen, CEO, Follicum AB
Phone: +46 (0)70 392 1331
Email: kim.nielsen@follicum.com
About Follicum AB
Follicum AB (Spotlight: FOLLI) develops drugs based on tissue repair peptides with potential use in a range of disease areas. The company's most advanced drug candidate, FOL-005, is administered using a unique formulation technology found safe and well-tolerated in a comprehensive Phase 2 study conducted in collaboration with internationally renowned specialist clinics. In the field of diabetes, a project is being conducted that aims to protect insulin-producing cells from damage, thus reducing the risk for complications. The projects have the potential to become so-called first-in-class medicines. For more information, visit www.follicum.com.